14 Dec 2018 07:50
14 December 2018
SalvaRx Group plc
("SalvaRx" or the "Company")
Nominated Adviser Status
SalvaRx announces that the Directors have been advised by its current nominated adviser ("Nomad"), Northland Capital Partners Limited ("Northland"), of its proposed merger with SP Angel Corporate Finance LLP ("SP Angel"). Northland has voluntarily agreed to relinquish its Nomad status and will be removed from the register of Nomads with effect from 7.00 a.m. on 1 February 2019.
As a result, it is the intention of the Directors to transition the Company's Nomad role from Northland to SP Angel. This process has already started and at present the Directors anticipate a smooth and orderly transition of the Nomad role.
Furthermore, the Company recognises that Northland's merger with SP Angel remains subject to regulatory approvals and due diligence. In accordance with AIM Rule 1, in the unlikely event that the Company fails to appoint a replacement Nomad by 1 February 2019 the Exchange will suspend trading in the Company's AIM Securities. In the event that the Company has failed to appoint a replacement Nomad by 4 March 2019, the admission of its AIM Securities will be cancelled.
Enquiries:
SalvaRx Group plc | ||
Ian Walters (Chief Executive) | Tel: +1 203-441-5451 | |
Northland Capital Partners Limited Nominated Adviser and Broker | Tel: +44 (0) 20 3861 6625
| |
Matthew Johnson / Edward Hutton (Corporate Finance) | ||
Vadim Alexandre (Corporate Broking) | ||
Peterhouse Capital Limited Joint Broker Lucy Williams / Duncan Vasey | Tel: +44 (0) 20 7469 0932 | |